Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes

Diabetologia

Volumn 57, Issue 5, 2014, Pages 891-901

  Polidori, David ^a   Mari, Andrea ^b   Ferrannini, Ele ^c  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b CNR   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

Beta cell function; Canagliflozin; Insulin secretion; SGLT2; Sodium glucose co transporter 2 inhibitor; Type 2 diabetes

Indexed keywords

C PEPTIDE; CANAGLIFLOZIN; GLUCOSE; INSULIN; METFORMIN; PLACEBO; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2; SULFONYLUREA; GLUCOSE BLOOD LEVEL; GLUCOSIDE; PYRAZINE DERIVATIVE; SLC5A2 PROTEIN, HUMAN; SULFONYLUREA DERIVATIVE; THIOPHENE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; ARTICLE; BODY WEIGHT; CELL FUNCTION; FEMALE; HUMAN; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; WAIST CIRCUMFERENCE; AGED; ANALYSIS; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; TIME;

ADULT; AGED; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLUCOSIDES; HUMANS; INSULIN-SECRETING CELLS; LEAST-SQUARES ANALYSIS; MALE; METFORMIN; MIDDLE AGED; PYRAZINES; SODIUM-GLUCOSE TRANSPORTER 2; SULFONYLUREA COMPOUNDS; THIOPHENES; TIME FACTORS; TRIAZOLES;

EID: 84898600889     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3196-x     Document Type: Article

References (31)

1. Kahn SE (2001) Clinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 86:4047-4058 (Pubitemid 32848511)
2. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, Defronzo RA (2005) Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab 90:493-500 (Pubitemid 40116699)
3. Jabbour S (2008) Primary care physicians and insulin initiation: multiple barriers, lack of knowledge or both? Int J Clin Pract 62:845-847 (Pubitemid 351691493)
4. Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35:1364-1379
5. Polidori D, Sha S, Mudaliar S et al (2013) Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care 36:2154-2161
6. Polidori D, Sha S, Ghosh A, Plum-Morschel L, Heise T, Rothenberg P (2013) Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 98:E867-E871
7. Rossetti L, Shulman GI, Zawalich W, Defronzo RA (1987) Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 80:1037-1044 (Pubitemid 18075639)
8. Nunoi K, Yasuda K, Adachi T et al (2002) Beneficial effect of T-1095, a selective inhibitor of renal Na+-glucose cotransporters, on metabolic index and insulin secretion in spontaneously diabetic GK rats. Clin Exp Pharmacol Physiol 29:386-390 (Pubitemid 34535357)
9. Katsuno K, Fujimori Y, Ishikawa-Takemura Y, Isaji M (2009) Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice. Eur J Pharmacol 618:98-104
10. Liang Y, Arakawa K, Ueta K et al (2012) Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS ONE 7:e30555
11. Bode B, Stenlof K, Sullivan D, Fung A, Usiskin K (2013) Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract 41:72-84
12. Cefalu WT, Leiter LA, Yoon K-H et al (2013) Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382:941-950
13. Lavalle-Gonzalez F, Januszewicz A, Davidson J et al (2013) Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 56:2582-2592
14. Rosenstock J, Aggarwal N, Polidori D et al (2012) Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 35:1232-1238
15. Schernthaner G, Gross JL, Rosenstock J et al (2013) Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial. Diabetes Care 36:2508-2515
16. Stenlöf K, Cefalu WT, Kim K-A et al (2013) Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 15:372-382
17. Yale JF, Bakris G, Cariou B et al (2013) Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 15:463-473
18. Wilding JP, Charpentier G, Hollander P et al (2013) Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 67:1267-1282
19. Mari A, Tura A, Gastaldelli A, Ferrannini E (2002) Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation. Diabetes 51(Suppl 1):S221-S226
20. Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E (2002) Meal and oral glucose tests for assessment of beta-cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab 283:E1159-E1166
21. Mari A, Ferrannini E (2008) Beta-cell function assessment from modelling of oral tests: an effective approach. Diabetes Obes Metab 10(Suppl 4):77-87
22. Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ (2001) A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 24:539-548 (Pubitemid 32198427)
23. Mari A, Bagger JI, Ferrannini E, Holst JJ, Knop FK, Vilsboll T (2013) Mechanisms of the incretin effect in subjects with normal glucose tolerance and patients with type 2 diabetes. PLoS ONE 8:e73154
24. Mari A, Sallas WM, He YL et al (2005) Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 90:4888-4894 (Pubitemid 41159387)
25. Muscelli E, Casolaro A, Gastaldelli A et al (2012) Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab 97:2818-2826
26. Mari A, Degn K, Brock B, Rungby J, Ferrannini E, Schmitz O (2007) Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions. Diabetes Care 30:2032-2033 (Pubitemid 47219415)
27. Mari A, Nielsen LL, Nanayakkara N, Defronzo RA, Ferrannini E, Halseth A (2006) Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea. Horm Metab Res 38:838-844 (Pubitemid 46051506)
28. Loopstra-Masters RC, Haffner SM, Lorenzo C, Wagenknecht LE, Hanley AJ (2011) Proinsulin-to-C-peptide ratio versus proinsulin-to-insulin ratio in the prediction of incident diabetes: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetologia 54:3047-3054
29. Sha S, Devineni D, Ghosh A et al (2011) Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 13:669-672
30. Cpep). Diabetes 62:A291-A292, Abstract
31. Radziuk J, Morishima T (1985) New methods for the analysis of insulin kinetics in vivo: insulin secretion, degradation, systemic dynamics and hepatic extraction. Adv Exp Med Biol 189:247-276